Noteworthy

Dec 18, 2017
Pharmaceutical Executive
With over 70 companies manufacturing immediate-release opioids in the United States, federal regulators may look to limit marketing to reduce the prescription and over-prescription of opioids.
Dec 12, 2017
Pharmaceutical Executive
Figuring out the right formula to address global health—for the better.
Dec 11, 2017
Pharmaceutical Executive
Groundbreaking treatment approaches call for innovative commercialization strategies.
Dec 11, 2017
Pharmaceutical Executive
In 2017, patients gained access to the first gene therapies and more orphan and breakthrough drugs.
Dec 10, 2017
Pharmaceutical Executive
How Ruud Dobber is steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.
Dec 05, 2017
Pharmaceutical Executive
Innovation by itself won't solve the complex multichannel challenges pharmas face. Jeff Greene reports.
Nov 30, 2017
Paul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.
Nov 30, 2017
Mark Bouch, Stephen Bungay, and David Roblin outline how the technique of "mission command", a military approach to setting direction and executing strategy in the pharmaceutical industry, has developed over the last ten years.
Nov 30, 2017
Pharmaceutical Executive
Analysis shows that persistence is paying off for drug developers, driven by the rise of CAR-T and other gene therapy, newly discovered cancer targets, better patient identification methods.
Nov 27, 2017
Halfway through the process for establishing a national electronic drug tracking system, there’s concern among pharma companies, distributors, and pharmacists about meeting the 2023 deadline
native1_300x100
lorem ipsum